Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

A technology of dimethyl propane and diabetes, applied to the use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium or its pharmaceutically acceptable salt in the prevention and treatment of diabetes areas that can address issues such as inadequate insulin control

CN105530929AActive Publication Date: 2016-04-27GRINDEKS
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2016-04-27

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts to decrease blood plasma levels of insulin and glucose.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium or its pharmaceutically acceptable salt for preventing and treating diabetes. Examples of pharmaceutically acceptable salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium are: 3-carboxy-N-ethyl-N,N-dimethylpropan- 1-Ammonium hydrogen fumarate and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium dihydrogenphosphate. Background technique

[0002] It is known that 3-carboxy-N,N,N-trimethylpropan-1-ammonium (GBB) is mainly a bioprecursor of carnitine, a key molecule regulating myocardial energy metabolism. It was initially characterized as a toxic substance that accelerated respiration, causing salivation and lacrimation, pupillary dilation, vasoconstriction and diastolic cardiac arrest (LINNEWEHW. , p.42-53). In later publications, it has been shown that 3-carboxy-N,N,N-trimethylpropan-1-ammonium has very low toxicity (LD 5O 7000 mg / kg, s.c.) (ROTZSCH.W.UberdieToxizita...

Examples

Embodiment Construction

[0012] Female ApoE weighing 18-20 g - / - Mice were kept in an air-conditioned room (22.5±0.5°C, 50±5% humidity) with a light-dark cycle of 12h dark / 12h light, with unrestricted access to food and water.

[0013] Mice were acclimated to the field environment for 1 week before starting the study. At 8 weeks of age, mice were randomly assigned to 5 equally sized groups (n=10). Experimental animals in all groups were fed for 4 months with WESTERNRD(P) feed (Cat 82316) from Special Diets Services (UK). During this 4-month period, mice in different experimental groups received the following treatments:

[0014] Control group – drinking water;

[0015] GBB group – GBB10mg / kg;

[0016] 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium hydrogen fumarate group – 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium fumarate Hydrogen maleate 17.5mg / kg;

[0017] 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium phosphate dihydrogen salt group – 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium p...